Evidence map›Paper›PMID 33599920›Full record

ArticleGeroScience2021

A robust machine learning framework to identify signatures for frailty: a nested case-control study in four aging European cohorts.

David Gomez-Cabrero, Stefan Walter, Imad Abugessaisa, Rebeca Miñambres-Herraiz, Lucia Bernad Palomares, Lee Butcher, Jorge D Erusalimsky, Francisco Jose Garcia-Garcia, José Carnicero, Timothy C Hardman and 27 more

Registry-linked trialAbstract read
In one paragraph

Article in GeroScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05500742 (The proBNPage Reduction), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05500742 naunknown statusnot on this mapstarted 2022, after this paper: background citation

The proBNPage Reduction (PBAR) Randomized Trial: a Pilot Study to Define the Characteristics of Future Randomized Trials Aimed at Evaluating the Effects of Anti-aging Treatments on a Surrogate of Biological Age in Healthy Older Adults

TypeinterventionalSponsorIRCCS Azienda Ospedaliero-Universitaria di BolognaRan2022 to 2024Enrolled120ConditionsAgingArmsCoenzyme Q10, Selenium, Resveratrol, TA-65 MD, Placebo-1
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Observational
  8. Poor olfaction and risk of heart failure in the Atherosclerosis Risk in Communities Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

David Gomez-CabreroTranslational Bioinformatics Unit, Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.ORCID https://orcid.org/0000-0003-4186-3788
Stefan WalterDept. of Medicine and Public Health, Rey Juan Carlos University, Alcorcon, Spain.
Imad AbugessaisaDept. of Medicine, Karolinska Institute, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-7458-801X
Rebeca Miñambres-HerraizSistemas Genomicos, Valencia, Spain.
Lucia Bernad PalomaresSistemas Genomicos, Valencia, Spain.ORCID https://orcid.org/0000-0002-1527-7315
Lee ButcherDepartment of Biomedical Sciences, Cardiff Metropolitan University, Cardiff, UK.
Jorge D ErusalimskyDepartment of Biomedical Sciences, Cardiff Metropolitan University, Cardiff, UK.ORCID https://orcid.org/0000-0002-4253-5789
Francisco Jose Garcia-GarciaDept. of Geriatric Medicine, Complejo Hospitalario Universitario de Toledo (CHUT), Toledo, Spain.ORCID https://orcid.org/0000-0003-3690-6069
José CarniceroDept. of Geriatric Medicine, Complejo Hospitalario Universitario de Toledo (CHUT), Toledo, Spain.
Timothy C HardmanNiche Science & Technology Ltd., Richmond-upon-Thames, London, UK.ORCID https://orcid.org/0000-0002-1417-9019
Harald MischakMosaiques Diagnostics GmbH, Rotenburger Str. 20, 30659, Hannover, Germany.ORCID https://orcid.org/0000-0003-0323-0306
Petra ZürbigMosaiques Diagnostics GmbH, Rotenburger Str. 20, 30659, Hannover, Germany.ORCID https://orcid.org/0000-0003-3465-2173
Matthias HacklEvercyte GmbH; BOKU-University of Natural Resources and Life Sciences Vienna, Department of Biotechnology, Ludwig Boltzmann Institute of Experimental and Clinical Traumatology, Vienna, Austria.ORCID https://orcid.org/0000-0002-4136-7293
Johannes GrillariEvercyte GmbH; BOKU-University of Natural Resources and Life Sciences Vienna, Department of Biotechnology, Ludwig Boltzmann Institute of Experimental and Clinical Traumatology, Vienna, Austria.ORCID https://orcid.org/0000-0001-5474-6332
Edoardo FiorilloInstituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Monserrato, Cagliari, Italy.ORCID https://orcid.org/0000-0002-8690-4988
Francesco CuccaInstituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche, Monserrato, Cagliari, Italy.ORCID https://orcid.org/0000-0002-7414-1995
Matteo CesariFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.ORCID https://orcid.org/0000-0002-0348-3664
Isabelle CarrieGérontopôle, Toulouse, France.
Marco ColpoUSL Centro Toscana, Firenze, Italy.
Stefania BandinelliUSL Centro Toscana, Firenze, Italy.
Catherine FeartUniv. Bordeaux, Bordeaux Population Health Research Center, UMR 1219, F-33000, Bordeaux, France.
Karine PeresUniv. Bordeaux, Bordeaux Population Health Research Center, UMR 1219, F-33000, Bordeaux, France.
Jean-François DartiguesUniv. Bordeaux, Bordeaux Population Health Research Center, UMR 1219, F-33000, Bordeaux, France.
Catherine HelmerUniv. Bordeaux, Bordeaux Population Health Research Center, UMR 1219, F-33000, Bordeaux, France.
José ViñaFreshage, University of Valencia, Valencia, Spain.ORCID https://orcid.org/0000-0001-9709-0089
Gloria OlasoFreshage, University of Valencia, Valencia, Spain.
Irene García-PalmeroLifelength, Madrid, Spain.
Jorge García MartínezLifelength, Madrid, Spain.ORCID https://orcid.org/0000-0001-6906-6268
Pidder Jansen-DürrResearch Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, Austria.
Tilman GruneGerman Institute for Human Nutrition, Potsdam, Germany.
Daniela WeberGerman Institute for Human Nutrition, Potsdam, Germany.ORCID https://orcid.org/0000-0002-2054-6233
Giuseppe LippiClinical Biochemistry and Molecular Biology, Universita di Verona, Verona, Italy.ORCID https://orcid.org/0000-0001-9523-9054
Chiara BonaguriLaboratoy Medicine Technical Sciences, Parma University, Parma, Italy.
Alan J SinclairDiabetes Frail and King's College, London, Se1 8WA, UK.
Jesper TegnerDept. of Medicine, Karolinska Institute, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-9568-5588
Leocadio Rodriguez-MañasCIBER of Frailty and Healthy Aging, Madrid, Spain. leocadio.rodriguez@salud.madrid.org.ORCID https://orcid.org/0000-0002-6551-1333
FRAILOMIC initiative

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phenotype-specific omic expression patterns in people with frailty could provide invaluable insight into the underlying multi-systemic pathological processes and targets for intervention. Classical approaches to frailty have not considered the potential for different frailty phenotypes. We characterized associations between frailty (with/without disability) and sets of omic factors (genomic, proteomic, and metabolomic) plus markers measured in routine geriatric care. This study was a prevalent case control using stored biospecimens (urine, whole blood, cells, plasma, and serum) from 1522 individuals (identified as robust (R), pre-frail (P), or frail (F)] from the Toledo Study of Healthy Aging (R=178/P=184/F=109), 3 City Bordeaux (111/269/100), Aging Multidisciplinary Investigation (157/79/54) and InCHIANTI (106/98/77) cohorts. The analysis included over 35,000 omic and routine laboratory variables from robust and frail or pre-frail (with/without disability) individuals using a machine learning framework. We identified three protective biomarkers, vitamin D3 (OR: 0.81 [95% CI: 0.68-0.98]), lutein zeaxanthin (OR: 0.82 [95% CI: 0.70-0.97]), and miRNA125b-5p (OR: 0.73, [95% CI: 0.56-0.97]) and one risk biomarker, cardiac troponin T (OR: 1.25 [95% CI: 1.23-1.27]). Excluding individuals with a disability, one protective biomarker was identified, miR125b-5p (OR: 0.85, [95% CI: 0.81-0.88]). Three risks of frailty biomarkers were detected: pro-BNP (OR: 1.47 [95% CI: 1.27-1.7]), cardiac troponin T (OR: 1.29 [95% CI: 1.21-1.38]), and sRAGE (OR: 1.26 [95% CI: 1.01-1.57]). Three key frailty biomarkers demonstrated a statistical association with frailty (oxidative stress, vitamin D, and cardiovascular system) with relationship patterns differing depending on the presence or absence of a disability.

Indexed as

FrailtyAgedCase-Control StudiesFrail ElderlyHumansMachine LearningProteomicsBiomarkersClinical phenotypeDisabilityFrailtyOmics

Identifiers

PMID33599920
PMCPMC8190217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.